Document is current
Any future updates will be listed below
-
Authors
Goel, Utkarsh https://orcid.org/0000-0003-1663-0325
Dima, Danai
Davis, James A. https://orcid.org/0000-0001-7978-1652
Rashid, Aliya
Wesson, William https://orcid.org/0000-0002-9534-0512
Williams, Louis
Mazzoni, Sandra https://orcid.org/0000-0001-7548-0705
Bhurtel, Evguenia
Ullah, Fauzia
Rudoni, Joslyn
Rice, Mikhaila https://orcid.org/0000-0002-4273-5780
Tiger, Yun Kyoung Ryu
Sauter, Craig S.
Anwer, Faiz https://orcid.org/0000-0001-6914-7439
Raza, Shahzad
Shune, Leyla
Khouri, Jack https://orcid.org/0000-0002-2473-6528
- License Information
-
More Information
Article History
Received: 20 February 2025
Revised: 14 April 2025
Accepted: 16 April 2025
First Online: 29 April 2025
Competing interests
: FA: Research Funding and Consultancy for BMS, Janssen, Allogene Therapeutics. JK: Consulting or advisory role for GPCR, Janssen, Prothena, Legend Biotech. Research funding for Prothena, Ascentage, Janssen, Karyopharm, GPCR. SR: Advisory board for Kite Pharma, Pfizer and Prothena biosciences. LW: Consulting for BMS, Janssen, Abbvie. CSS: Consultancy for Kite/a Gilead Company, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics and GSK; Research Funding for Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme and NKARTA. The remaining authors declare no competing interests.
: This study was IRB approved and was conducted under the Declaration of Helsinki. A waiver of informed consent was approved based on the retrospective nature of the study.
